Corona pricing is pricing .. and expectations of higher demand

0
4


DexamethasoneAffiliated, widely available steroids family, has drastically reduced mortality among critical cases with Covid-19 disease.

Demand is expected to rise on Remdisiver As one of the treatments, it turned out to be changing the course of Covid-19.

After the drug, which was taken intravenously, shortened hospitalizations in clinical trials, he obtained approval for use in severe cases in the United States and obtained full approval in Japan.

And for For American patients, Who have commercial insurance, Gilliad said that a 5-day course of treatment will cost $ 3,120, or $ 520 per bottle.

That is 33 percent higher than the $ 390 per bottle, which Gilead said it would charge to developed country governments and US patients in government health care programs.

In an open letter, Gilliad CEO Daniel Oday said the price was far below the value it provided given that early hospital discharge could save about $ 12,000 to a patient in the United States.

Patient advocacy bodies, such as Public Citizen, argue that the cost should be lower because Remediesever was developed with financial support from the government. United State.

And she said Gilliad Also, it has agreed to continue sending its supplies from Remdisfer to the US Department of Health and Human Services until the end of September.

“>

This price is slightly lower than the range between $ 2520 and $ 2,800, which was proposed last week by the Clinical and Economic Review Institute, a US agency that researches drug prices, after British researchers said they found a drug DexamethasoneAffiliated, widely available steroids family, has drastically reduced mortality among critical cases with Covid-19 disease.

Demand is expected to rise on Remdisiver As one of the treatments, it turned out to be changing the course of Covid-19.

After the drug, which was taken intravenously, shortened hospitalizations in clinical trials, he obtained approval for use in severe cases in the United States and obtained full approval in Japan.

And for For American patients, Who have commercial insurance, Gilliad said that a 5-day course of treatment will cost $ 3,120, or $ 520 per bottle.

That is 33 percent higher than the $ 390 per bottle, which Gilead said it would charge to developed country governments and US patients in government health care programs.

In an open letter, Gilliad CEO Daniel Oday said the price was far below the value it provided given that early hospital discharge could save about $ 12,000 to a patient in the United States.

Patient advocacy bodies, such as Public Citizen, argue that the cost should be lower because Remediesever was developed with financial support from the government. United State.

And she said Gilliad Also, it has agreed to continue sending its supplies from Remdisfer to the US Department of Health and Human Services until the end of September.



LEAVE A REPLY

Please enter your comment!
Please enter your name here